Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.
According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.
Dianthus Therapeutics director Jonathan Violin received a compensation-related stock option grant. He was awarded options to purchase 6,090 shares of common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that date. After this grant, he holds 6,090 stock options directly, with no open-market share purchases or sales reported in this filing.
Dianthus Therapeutics director Paula Soteropoulos received a grant of stock options covering 6,090 shares of common stock. These options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 derivative securities linked to common stock.
The underlying 6,090 shares of common stock will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through the vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Dianthus Therapeutics reported results from its annual stockholder meeting held on May 21, 2026. Stockholders elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting. An advisory vote approved executive compensation, with 41,004,507 votes for and 1,713,043 against. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,298,319 votes for and minimal opposition.
Dianthus Therapeutics ownership update: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial ownership of 2,611,733 shares of Common Stock, equal to 4.8%, reported as of March 31, 2026.
The filing states the Fund directly holds 2,611,733 shares, that the percentage is calculated using 54,448,771 shares outstanding as of March 30, 2026, and that RA Capital has been delegated voting and dispositive power over the Fund's holdings. The Reporting Persons disclaim group status and disclaim beneficial ownership for purposes described in the text.
Dianthus Therapeutics filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 643,599 shares of Common Stock, representing 1.2% of the class as of the close of business on March 31, 2026.
The filing identifies Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as the reporting persons; the shares are held through an investment fund managed by Point72 and are reported as shared voting and dispositive power. The percentage basis is an aggregate of 52,942,083 Shares outstanding derived from offering and prior outstanding counts disclosed in the filing.
Dianthus Therapeutics reported that Sirenia Capital Management and Alex Silverstein together hold 2,798,122 shares, representing 5.3% of the outstanding common stock. The filing states the outstanding share count used for the percentage was 52,942,083 shares (aggregate basis).
The reported position includes 500,000 shares issuable upon exercise of call options. The disclosure is made via a joint Schedule 13G filing under Rule 13d-1(k).
Dianthus Therapeutics, Inc. Schedule 13G/A filed by Wellington Management Group LLP and related entities reports beneficial ownership of 2,595,783 shares of common stock, representing 4.77% of the class. The filing attributes shared voting power of 2,358,243 and shared dispositive power of 2,595,783. The cover pages list the holdings across Wellington affiliates and identify the reporting structure of parent and adviser entities. The signatures show the filing was executed on 05/15/2026.
Dianthus Therapeutics ownership update: This Amendment No. 3 to a Schedule 13G/A states that Octagon-related reporting persons collectively beneficially own 1,946,667 shares of Dianthus Therapeutics common stock, equal to 3.6% of the class based on 54,448,771 shares outstanding as of March 30, 2026. The filing attributes shared voting and dispositive power over those shares to Octagon and identifies Octagon and affiliated funds as holders.